Skip Navigation


NDT Advance Access originally published online on February 22, 2005
Nephrology Dialysis Transplantation 2005 20(4):846; doi:10.1093/ndt/gfh678
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/4/846    most recent
gfh678v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Boucher, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boucher, B. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Reduced cardiovascular mortality in oral 1{alpha}-hydroxy vitamin D3 users in a haemodialysis population; do CRP and MMP markers of inflammation reflect this finding?

The first 10% of the full text of this article appears below.

Sir,

I found the paper ‘Lower risk for cardiovascular mortality in oral 1{alpha}. . . [Full Text of this Article]

Barbara J. Boucher

Centre for Diabetes and Metabolic Medicine [Bart's and the London Queen Mary School of Medicine and Dentistry] Royal London Hospital London E1 1BB UK Email: bboucher@doctors.org.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?